Products Categories
| CAS No.: | 220127-57-1 |
|---|---|
| Name: | Imatinib mesylate |
| Article Data: | 54 |
| Molecular Structure: | |
|
|
|
| Formula: | C29H31N7O.CH4O3S |
| Molecular Weight: | 589.71 |
| Synonyms: | Benzamide, 4-[ (4-methyl-1-piperazinyl)methyl]-N-[[4- methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate;Matinib mesylate;Imatinib Methanesulfonate;Imatinibmesylate & its intermediates;4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide methanesulfonic acid salt;Veenat;4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3- (4-pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamidemethanesulf onic acid salt;methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; |
| EINECS: | 606-892-3 |
| Density: | 0.858g/mLat 25°C(lit.) |
| Melting Point: | 214-224°C |
| Boiling Point: | 754.9 °C at 760 mmHg |
| Flash Point: | 410.3 °C |
| Appearance: | Off-white solid |
| Hazard Symbols: | Xn |
| Risk Codes: | 22 |
| PSA: | 149.03000 |
| LogP: | 5.19690 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 240444-70-62,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropancarboxylat
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 114977-28-5Docetaxel
- 137862-53-4Valsartan
- 303-98-0Ubidecarenone
- 150322-43-3Prasugrel
- 184475-35-2Gefitinib
- 179324-69-7Bortezomib
- 366789-02-8Rivaroxaban
- 56038-13-2Sucralose
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
1. Introduction of Imatinib mesylate
Imatinib mesylate is off-white solid. The IUPAC Name of this chemical is Methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide. In addition, its Classification Code is Antineoplastic. Besides, Imatinib mesylate belongs to Active Pharmaceutical Ingredients; Intermediates & Fine Chemicals; Pharmaceuticals; Tyrosine Kinase Inhibitors. Imatinib mesylate is soluble in aqueous buffers ≤ pH 5.5 but is very slightly soluble to insoluble in neutral/alkaline aqueous buffers.
2. Properties of Imatinib mesylate
Physical properties about Imatinib mesylate are:
(1)H-Bond Donor: 3; (2)H-Bond Acceptor: 10; (3)Flash Point: 410.3 °C; (4)Enthalpy of Vaporization: 115.42 kJ/mol; (5)Boiling Point: 754.9 °C at 760 mmHg; (6)Vapour Pressure of Imatinib mesylate (CAS NO.220127-57-1): 6.03E-24 mmHg at 25 °C.
3. Structure Descriptors of Imatinib mesylate
(1)Canonical SMILES: C1N(C)CCN(C1)Cc1ccc(cc1)C(Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C)=O.OS(C)(=O)=O
(2)InChI: InChI=1/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
(3)InChIKey: InChIKey=YLMAHDNUQAMNNX-UHFFFAOYSA-N
(4)Smiles: C1N(C)CCN(C1)Cc1ccc(cc1)C(Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C)=O.OS(C)(=O)=O
4. Uses of Imatinib mesylate
Imatinib mesylate (CAS NO.220127-57-1) is used as a tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It can inhibits Bcr-Abl protein-tyrosine kinase.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.